U.S. markets open in 4 hours 36 minutes

Ambu A/S (AMBU-B.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
195.00-0.60 (-0.31%)
As of 10:54AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close195.60
Open195.00
Bid194.90 x 0
Ask195.10 x 0
Day's Range193.40 - 196.30
52 Week Range94.60 - 241.90
Volume119,464
Avg. Volume850,053
Market Cap49.299B
Beta (5Y Monthly)0.13
PE Ratio (TTM)331.07
EPS (TTM)0.59
Earnings DateN/A
Forward Dividend & Yield0.38 (0.19%)
Ex-Dividend DateDec 18, 2019
1y Target Est230.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Ambu A/S: Chairman of the Board of Directors will not seek re-election

      Lars Rasmussen, who has been chairman of the Board of Directors in Ambu A/S since December 2019, has decided not to seek re-election at the Annual General Meeting in December 2020.“It has been brought to my attention, that certain Ambu shareholders are of the opinion that there is a potential conflict of interest by me being chairman of the Board of Directors in both Ambu and Coloplast. The reason is, that Coloplast during its recent Capital Markets Day mentioned that they might sometime in the future evaluate if distribution of cystoscopes could be a new product area to enter. Based on this potential future uncertainty, I have decided not to seek re-election as chairman of the Board of Directors in Ambu to make sure that I and the company apply to the highest corporate governance standards,” says Lars Rasmussen about the unexpected departure from Ambu.Oliver Johansen, who has been a member of the Board in Ambu A/S since 2015 and who is SVP, Global R&D with Coloplast, has also decided not to seek re-election at the Annual General Meeting for the same reason as Lars Rasmussen.The search for new candidates will be initiated in line with Ambu’s Board succession planning process.The entire Board would like to thank Lars Rasmussen as well as Oliver Johansen for their contribution to Ambu’s successful development during their tenure.Contact Lars Rasmussen, chairman of the Board of Directors, tel. +45 4911 1149.Attachment * Company announcement no.1 2020-21

    • GlobeNewswire

      Ambu A/S: Financial calendar

      Ambu's financial calendar for fiscal year 2020/21 is hereby announced.Contact Michael Højgaard, CFO, tel. +45 4030 4349, email: miho@ambu.comAttachment * Company_Announcement_no. 15 2019-20

    • GlobeNewswire

      Ambu A/S: Capital increase in connection with exercise of warrants issued

      Capital increase in connection with exercise of warrantsAmbu A/S issued 2,000,000 warrants in 2014, 770,000 warrants in 2015, and 419,500 warrants in November 2016. Each warrant entitles the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 22 individuals participate in the 2014 scheme, 46 individuals participate in the 2015 scheme, and 71 individuals participate in the 2016 scheme.For all three schemes the vesting period is three years, and all three schemes can therefore be exercised in the trading window that opened on 26 August 2020 in connection with Ambu’s interim financial report for Q3 2019/20.Since 26 August 2020, instructions have been received to exercise warrants as follows: * 2014 scheme: Four individuals have issued instructions to exercise 400,000 warrants at the agreed exercise price of DKK 23.06 per share with a nominal value of DKK 0.50. * 2015 scheme: Ten individuals have issued instructions to exercise 185,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50. * 2016 scheme: One individual has issued instructions to exercise a total of 7,500 warrants at the agreed exercise price of DKK 77.12 per share with a nominal value of DKK 0.50.Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 296,250 from  DKK 108,952,300 to DKK 109,248,550 through the issue of 592,500 Class B shares.Following this and in consideration of the employees having left the company, the following warrants remain under the said schemes: * 2015 scheme: 115,000 remaining warrants being held by 11 individuals. * 2016 scheme: 242,000 remaining warrants being held by 45 individuals.The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 9 September 2020 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).Under section 32 of the Danish Capital Markets Act, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.  Number of shares (nominal value DKK 0.50)Nominal value (DKK)Voting rights A shares34,320,00017,160,000343,200,000 B shares218,497,100109,248,550218,497,100 Total252,817,100126,408,550561,697,100 ContactMichael Højgaard, CFO, tel. +45 4030 4349, email: miho@ambu.comAmbu A/S Baltorpbakken 13 2750 Ballerup, Denmark Tel. +45 7225 2000 CVR no.: 63 64 49 19 www.ambu.comAbout Ambu Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world’s first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,000 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com. Attachment * 20200903 Company_Announcement_no. 14 2019_20